Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00602667 · OUTCOME

Neurocognitive Performance Related to Working Memory as Measured by Working Memory T-scores

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
score on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy

What was measured

Scores measuring working memory were obtained from Working Memory T-scores, which were obtained from the Behavior Rating Inventory of Executive Function (BRIEF) instrument which is a parent report. Higher scores indicate more problems. The normative mean is 50 with a standard deviation of 10.

Analysis population: Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.

Groups in this outcome

Low-Risk Group

Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.

Intermediate-Risk Group

Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.

High-Risk Group

Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Low-Risk Group40
Intermediate-Risk Group85
High-Risk Group34

Reported measurements

Baseline

Analysis denominator · Participants

GroupSource count
Low-Risk Group13
Intermediate-Risk Group48
High-Risk Group22
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group63.216.0Not reportedNot reportedNot reported
Intermediate-Risk Group51.610.8Not reportedNot reportedNot reported
High-Risk Group57.013.6Not reportedNot reportedNot reported
Prior to Maintenance Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group12
Intermediate-Risk Group44
High-Risk Group9
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group58.710.7Not reportedNot reportedNot reported
Intermediate-Risk Group55.513.3Not reportedNot reportedNot reported
High-Risk Group54.111.1Not reportedNot reportedNot reported
Completion of Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group17
Intermediate-Risk Group41
High-Risk Group3
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group60.814.9Not reportedNot reportedNot reported
Intermediate-Risk Group54.911.1Not reportedNot reportedNot reported
High-Risk Group49.016.8Not reportedNot reportedNot reported
12 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group22
Intermediate-Risk Group39
High-Risk Group9
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group64.416.1Not reportedNot reportedNot reported
Intermediate-Risk Group60.414.5Not reportedNot reportedNot reported
High-Risk Group67.722.3Not reportedNot reportedNot reported
24 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group20
Intermediate-Risk Group38
High-Risk Group10
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group63.617.8Not reportedNot reportedNot reported
Intermediate-Risk Group59.414.7Not reportedNot reportedNot reported
High-Risk Group55.413.3Not reportedNot reportedNot reported
36 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group15
Intermediate-Risk Group32
High-Risk Group6
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group59.313.9Not reportedNot reportedNot reported
Intermediate-Risk Group62.014.2Not reportedNot reportedNot reported
High-Risk Group61.78.6Not reportedNot reportedNot reported
48 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group16
Intermediate-Risk Group34
High-Risk Group6
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group60.916.1Not reportedNot reportedNot reported
Intermediate-Risk Group60.013.1Not reportedNot reportedNot reported
High-Risk Group54.512.8Not reportedNot reportedNot reported
60 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group16
Intermediate-Risk Group21
High-Risk Group5
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group56.813.3Not reportedNot reportedNot reported
Intermediate-Risk Group60.614.3Not reportedNot reportedNot reported
High-Risk Group61.015.3Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.0
        value
        63.2
      2. group Id
        OG001
        spread
        10.8
        value
        51.6
      3. group Id
        OG002
        spread
        13.6
        value
        57.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        13
      2. group Id
        OG001
        value
        48
      3. group Id
        OG002
        value
        22
      units
      Participants
    title
    Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        10.7
        value
        58.7
      2. group Id
        OG001
        spread
        13.3
        value
        55.5
      3. group Id
        OG002
        spread
        11.1
        value
        54.1
    denoms
    1. counts
      1. group Id
        OG000
        value
        12
      2. group Id
        OG001
        value
        44
      3. group Id
        OG002
        value
        9
      units
      Participants
    title
    Prior to Maintenance Therapy
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        14.9
        value
        60.8
      2. group Id
        OG001
        spread
        11.1
        value
        54.9
      3. group Id
        OG002
        spread
        16.8
        value
        49.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        17
      2. group Id
        OG001
        value
        41
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    Completion of Therapy
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.1
        value
        64.4
      2. group Id
        OG001
        spread
        14.5
        value
        60.4
      3. group Id
        OG002
        spread
        22.3
        value
        67.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        22
      2. group Id
        OG001
        value
        39
      3. group Id
        OG002
        value
        9
      units
      Participants
    title
    12 Months Off Therapy
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        17.8
        value
        63.6
      2. group Id
        OG001
        spread
        14.7
        value
        59.4
      3. group Id
        OG002
        spread
        13.3
        value
        55.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        20
      2. group Id
        OG001
        value
        38
      3. group Id
        OG002
        value
        10
      units
      Participants
    title
    24 Months Off Therapy
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        13.9
        value
        59.3
      2. group Id
        OG001
        spread
        14.2
        value
        62.0
      3. group Id
        OG002
        spread
        8.6
        value
        61.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        15
      2. group Id
        OG001
        value
        32
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    36 Months Off Therapy
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.1
        value
        60.9
      2. group Id
        OG001
        spread
        13.1
        value
        60.0
      3. group Id
        OG002
        spread
        12.8
        value
        54.5
    denoms
    1. counts
      1. group Id
        OG000
        value
        16
      2. group Id
        OG001
        value
        34
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    48 Months Off Therapy
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        13.3
        value
        56.8
      2. group Id
        OG001
        spread
        14.3
        value
        60.6
      3. group Id
        OG002
        spread
        15.3
        value
        61.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        16
      2. group Id
        OG001
        value
        21
      3. group Id
        OG002
        value
        5
      units
      Participants
    title
    60 Months Off Therapy
denoms
  1. counts
    1. group Id
      OG000
      value
      40
    2. group Id
      OG001
      value
      85
    3. group Id
      OG002
      value
      34
    units
    Participants
description
Scores measuring working memory were obtained from Working Memory T-scores, which were obtained from the Behavior Rating Inventory of Executive Function (BRIEF) instrument which is a parent report. Higher scores indicate more problems. The normative mean is 50 with a standard deviation of 10.
dispersion Type
Standard Deviation
groups
  1. description
    Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.
    id
    OG000
    title
    Low-Risk Group
  2. description
    Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
    id
    OG001
    title
    Intermediate-Risk Group
  3. description
    Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.
    id
    OG002
    title
    High-Risk Group
param Type
MEAN
population Description
Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.
reporting Status
POSTED
time Frame
Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy
title
Neurocognitive Performance Related to Working Memory as Measured by Working Memory T-scores
type
SECONDARY
unit Of Measure
score on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice